Price Chart

Executive Summary

HC Wainwright & Co. initiated coverage on Ascendis Pharma A/S (ASND) at Buy with a price target of $345, implying 31% upside from the current $263.04. The firm has a 43% accuracy rate on 4,591 calls and an average return of 2.4%, placing it below average among covering firms. Consensus is overwhelmingly bullish — 25 of 26 analysts rate the stock Buy, with only one Hold and no Sell. The mean target is $315.17, median $313.81, high $362.26, and low $270.72. HC Wainwright's $345 target sits above both the mean and median, reflecting an above-consensus view. Momentum is constructive with 2 upgrades and 0 downgrades in the past 30 days, though EPS estimates for the current quarter and year have been revised downward over the past week and month. Insider activity is noteworthy — the Chief Business Officer bought $492,654 worth of shares on August 14, a bullish signal that aligns with the initiation. However, several institutions exited positions completely and short interest sits at a high 68.8% of float, creating a potential squeeze but also elevated risk. The bottom line: a historically below-average firm initiating at Buy with an above-consensus target is moderately bullish but not a game-changer on its own.

Impact Score

Consensus & Targets

Consensus is 96% Buy — 12 Strong Buy, 13 Buy, 1 Hold, 0 Sell, 0 Strong Sell from 26 analysts. Direction is heavily bullish, with no bearish or strongly bearish ratings. This initiation reinforces that existing skew.

Current price: $263.04. Mean target: $315.17 (implied +19.8%). Median: $313.81. High: $362.26. Low: $270.72. HC Wainwright's $345 PT is above the mean and median, ranking near the top of the range alongside the high target. Implied upside: +31.2% to this firm's target vs +19.8% to consensus mean.

Recent Analyst Activity

30-day analyst activity: 2 upgrades, 0 downgrades. Recent actions include Wedbush reiterating Outperform ($327), B of A maintaining Buy ($304), Jefferies maintaining Buy ($330), Stifel maintaining Buy ($326), and HC Wainwright maintaining Buy ($344) after initiation. EPS revisions trend is negative — current quarter EPS estimate fell 27.8% over 7 days (from $1.317 to $0.95), and current year estimate fell 3.4% (from $11.731 to $11.337). However, 1 revision up in the past 7 days for both current year and next year suggests recent stabilization.

Firm Track Record — HC Wainwright & Co.

HC Wainwright & Co. accuracy: 43% on 4591 calls | avg return: 2.4%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 14 firms with ≥5 scored calls.

HC Wainwright has a 43% accuracy rate on 4,591 rated calls, below the average for firms covering ASND. Their average return is 2.4%. Top-tier firms by accuracy on ASND include RBC Capital (100%, 3/3), Wedbush (100%, 4/4), TD Cowen (100%, 4/4), and Stifel (100%, 4/4). B of A Securities and Oppenheimer each have 80% (4/5). The worst-performing is Goldman Sachs at 33% (1/3) with a -0.2% avg return. HC Wainwright's record is below most peers covering this name.

Earnings Estimates

Cross-Platform Signals

Insider trades: Chief Business Officer Bienaimé made two large purchases totaling $492,654 on August 14 — a bullish signal that aligns with the initiation. No congressional trades reported. Institutional changes show several notable exits, including Avoro Capital, RA Capital Management, and FRED ALGER MANAGEMENT all exiting positions completely (100% reduction to $0). Short interest is elevated at 68.8% of float (357,768 shares short), which is high and suggests potential squeeze dynamics, but also reflects bearish positioning. The insider buying divergence from institutional exits and high short interest creates a mixed picture — insiders see value while institutions and shorts are negative.

Investment Themes

Documents Analyzed

Report based on filing metadata.

US Market Status